ERBB2 and triple-negative breast carcinoma: This finding is consistent with existing literature that indicates high rates of aggressive EOL treatment for metastatic breast cancer.32 However, our study excluded patients receiving oral therapies, which may have unintentionally led to the inclusion of individuals with more aggressive disease subtypes such as hormone-resistant, HER2-positive, and triple-negative breast cancer.